Loading clinical trials...
Loading clinical trials...
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Conditions
Interventions
fluticasone propionate/salmeterol inhalation powder DISKUS 250/50
tiotropium bromide inhalation powder HandiHaler
Locations
27
United States
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Torrance, California, United States
GSK Investigational Site
Fort Collins, Colorado, United States
GSK Investigational Site
Hartford, Connecticut, United States
GSK Investigational Site
Saint Charles, Missouri, United States
Start Date
July 19, 2010
Primary Completion Date
May 1, 2011
Completion Date
May 2, 2011
Last Updated
November 8, 2017
NCT06712563
NCT07518472
NCT06831994
NCT05730088
NCT02755974
NCT07363980
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions